GT200700077A - Compuestos de 4-metilpiridopirimidinona - Google Patents

Compuestos de 4-metilpiridopirimidinona

Info

Publication number
GT200700077A
GT200700077A GT200700077A GT200700077A GT200700077A GT 200700077 A GT200700077 A GT 200700077A GT 200700077 A GT200700077 A GT 200700077A GT 200700077 A GT200700077 A GT 200700077A GT 200700077 A GT200700077 A GT 200700077A
Authority
GT
Guatemala
Prior art keywords
compounds
methylpiridopirimidinone
phosfoinositized
quinase
modulators
Prior art date
Application number
GT200700077A
Other languages
English (en)
Inventor
Hengmiao Cheng
Dilip Bhumralkar
Klaus Ruprecht Dress
Jacqui Elizabeth Hoffman
Mary Catherine Johnson
Robert Steven Kania
Phuong Thi Quy Le
Mitchell David Nambu
Mason Alan Pairish
Michael Bruno Plewe
Khanh Tuan Tran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200700077A publication Critical patent/GT200700077A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMULA GENERAL I EN LA QUE R1,R2,R3,R4,Z, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON MODULADORES O INHIBIDORES DE LA ENZIMA FOSFOINOSITIDO 3-QUINASA ALFA POR LO QUE SON DE UTILIDAD EN CUADROS O ESTADOS PATOLÓGICOS ASOCIADOS A CRECIMIENTO ANORMAL DE CÉLULAS TALES COMO EL CÁNCER.
GT200700077A 2006-09-15 2007-09-13 Compuestos de 4-metilpiridopirimidinona GT200700077A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US94785207P 2007-07-03 2007-07-03
US95262807P 2007-07-30 2007-07-30

Publications (1)

Publication Number Publication Date
GT200700077A true GT200700077A (es) 2009-08-03

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200700077A GT200700077A (es) 2006-09-15 2007-09-13 Compuestos de 4-metilpiridopirimidinona

Country Status (42)

Country Link
US (3) US7696213B2 (es)
EP (1) EP2074122B9 (es)
JP (1) JP4718637B2 (es)
KR (1) KR101099926B1 (es)
CN (1) CN101573358B (es)
AP (1) AP2710A (es)
AR (1) AR062785A1 (es)
AT (1) ATE514695T1 (es)
AU (1) AU2007297212B8 (es)
BR (1) BRPI0716749B8 (es)
CA (1) CA2663401C (es)
CL (1) CL2007002682A1 (es)
CR (1) CR10662A (es)
CU (1) CU23783B7 (es)
CY (1) CY1111911T1 (es)
DK (1) DK2074122T5 (es)
DO (1) DOP2009000039A (es)
EA (1) EA016388B1 (es)
ES (1) ES2366489T3 (es)
GE (1) GEP20115306B (es)
GT (1) GT200700077A (es)
HK (1) HK1138589A1 (es)
HN (1) HN2007000267A (es)
HR (1) HRP20110621T2 (es)
IL (1) IL197243A (es)
MA (1) MA30709B1 (es)
ME (1) MEP8009A (es)
MX (1) MX2009002927A (es)
MY (1) MY146420A (es)
NI (1) NI200900032A (es)
NO (1) NO342357B1 (es)
NZ (1) NZ575167A (es)
PE (1) PE20080670A1 (es)
PL (1) PL2074122T3 (es)
PT (1) PT2074122E (es)
RS (2) RS20090104A (es)
SI (1) SI2074122T1 (es)
TN (1) TN2009000085A1 (es)
TW (1) TWI334353B (es)
UY (1) UY30588A1 (es)
WO (1) WO2008032162A1 (es)
ZA (1) ZA200901477B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002927A (es) * 2006-09-15 2009-03-31 Pfizer Prod Inc Compuestos de pirido (2,3-d)pirimidinona y su uso como inhibidores de la enzima fosfoinositido 3.
ME00936B (me) * 2007-04-10 2012-06-20 Exelixis Inc Postupci liječenja kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
AU2008239596B2 (en) * 2007-04-11 2013-08-15 Exelixis, Inc. Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-alpha for the treatment of cancer
CA2729914A1 (en) 2008-07-11 2010-01-14 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
WO2010022125A1 (en) 2008-08-20 2010-02-25 Schering Corporation Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020238A (en) * 2008-08-20 2010-06-01 Schering Corp Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009282567B2 (en) 2008-08-20 2014-10-02 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5654990B2 (ja) 2008-08-20 2015-01-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アゾ置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
AR073524A1 (es) * 2008-09-30 2010-11-10 Exelixis Inc Piridopirimidinonas inhibidores de pi3k a y m tor
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
BR112013014914B8 (pt) 2010-12-16 2020-08-04 Hoffmann La Roche composto, composição farmacêutica e uso de um composto
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
US9675595B2 (en) 2011-08-31 2017-06-13 Novartis Ag Synergistic combinations of PI3K- and MEK-inhibitors
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
EP3172214B1 (en) 2014-07-26 2020-05-13 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
EP3204005A1 (en) 2014-10-10 2017-08-16 Pfizer Inc Synergistic auristatin combinations
HUE047477T2 (hu) 2015-06-04 2020-04-28 Pfizer Palbociclib szilárd dózisformái
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP3481822B1 (en) 2016-07-06 2022-06-22 The Regents of The University of Michigan Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
JP6563623B1 (ja) 2016-08-15 2019-08-21 ファイザー・インク ピリドピリミジノンｃｄｋ２／４／６阻害剤
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
EP3813946B1 (en) 2018-06-15 2024-05-22 Janssen Pharmaceutica NV Rapamycin analogs and uses thereof
CA3124574A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020140053A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
BR112022010754A2 (pt) 2019-12-05 2022-08-23 Anakuria Therapeutics Inc Análogos de rapamicina e usos dos mesmos
CN114901664A (zh) * 2020-01-10 2022-08-12 江苏先声药业有限公司 吡啶酮化合物及应用
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
KR20230121758A (ko) 2020-11-18 2023-08-21 데시페라 파마슈티칼스, 엘엘씨. Gcn2 및 perk 키나제 억제제 및 그의 사용 방법
WO2023092104A1 (en) * 2021-11-18 2023-05-25 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
TJ342B (en) 1994-11-14 2002-10-06 Warner Lambert Co Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
EP0964864B1 (en) 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
JP2003523358A (ja) 2000-01-27 2003-08-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 神経変性疾患の治療のためのピリドピリミジノン誘導体
IL151480A0 (en) 2000-03-06 2003-04-10 Warner Lambert Co 5-alkylpyrido[2,3-d] pyrimidines tyrosine kinase inhibitors
EP1277738B1 (en) 2000-04-27 2011-03-30 Astellas Pharma Inc. Condensed heteroaryl derivatives
EP1364950A4 (en) 2001-02-26 2005-03-09 Tanabe Seiyaku Co PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
CN101001857B (zh) 2002-01-22 2011-06-22 沃尼尔·朗伯有限责任公司 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
PL373339A1 (en) 2002-04-19 2005-08-22 Smithkline Beecham Corporation Novel compounds
CN1653077A (zh) 2002-05-06 2005-08-10 健亚生物科技公司 治疗c型肝炎病毒感染的核苷衍生物
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換６，６−ヘテロ二環式誘導体
US20050009849A1 (en) 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
JP2007504283A (ja) 2003-05-20 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア β−アミロイド斑に作用物質を結合させる方法
CN1835951B (zh) 2003-07-11 2010-06-02 沃尼尔·朗伯有限责任公司 选择性cdk4抑制剂的羟乙基磺酸盐
NZ544697A (en) 2003-07-22 2009-03-31 Janssen Pharmaceutica Nv Quinolinone derivatives as inhibitors of c-fms kinase
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
AU2005214352B2 (en) 2004-02-14 2009-11-12 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2007523151A (ja) 2004-02-18 2007-08-16 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ２−（ピリジン−３−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
JP2007530654A (ja) 2004-03-30 2007-11-01 ファイザー・プロダクツ・インク シグナル伝達阻害剤の組合せ
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
CA2563669A1 (en) * 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
CA2569277A1 (en) 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
WO2006021547A1 (de) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinone als plk (polo like kinase) inhibitoren
US7608594B2 (en) 2004-11-03 2009-10-27 University Of Kansas Novobiocin analogues as anticancer agents
WO2006065703A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
WO2007044698A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
WO2007044813A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
EP1872922A1 (en) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Method and apparatus for manufacturing a polymeric article
EP2056829B9 (en) 2006-08-16 2012-09-26 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
MX2009002927A (es) * 2006-09-15 2009-03-31 Pfizer Prod Inc Compuestos de pirido (2,3-d)pirimidinona y su uso como inhibidores de la enzima fosfoinositido 3.
CA2680796A1 (en) * 2007-03-14 2008-09-18 Exelixis, Inc. Inhibitors of the hedgehog pathway
AU2008239596B2 (en) * 2007-04-11 2013-08-15 Exelixis, Inc. Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-alpha for the treatment of cancer
AR073524A1 (es) * 2008-09-30 2010-11-10 Exelixis Inc Piridopirimidinonas inhibidores de pi3k a y m tor
CN102970868A (zh) * 2010-04-16 2013-03-13 柯瑞斯公司 具有k-ras突变的癌症的治疗

Also Published As

Publication number Publication date
AP2009004790A0 (en) 2009-04-30
NI200900032A (es) 2010-05-14
DK2074122T5 (da) 2014-03-17
SI2074122T1 (sl) 2011-10-28
PT2074122E (pt) 2011-08-24
DK2074122T3 (da) 2011-08-15
NZ575167A (en) 2010-10-29
HK1138589A1 (en) 2010-08-27
CU23783B7 (es) 2012-02-15
UY30588A1 (es) 2008-05-02
MY146420A (en) 2012-08-15
RS51927B (en) 2012-02-29
HRP20110621T2 (hr) 2013-12-06
DOP2009000039A (es) 2015-12-15
CU20090040A7 (es) 2011-07-11
US20120309775A1 (en) 2012-12-06
CL2007002682A1 (es) 2008-04-04
AU2007297212B2 (en) 2011-04-14
IL197243A (en) 2013-07-31
KR20090040389A (ko) 2009-04-23
MA30709B1 (fr) 2009-09-01
PE20080670A1 (es) 2008-06-14
CY1111911T1 (el) 2015-11-04
AP2710A (en) 2013-07-30
MX2009002927A (es) 2009-03-31
US8273755B2 (en) 2012-09-25
MEP8009A (en) 2011-12-20
IL197243A0 (en) 2009-12-24
ZA200901477B (en) 2010-07-28
US20080090801A1 (en) 2008-04-17
HRP20110621T1 (en) 2011-09-30
EP2074122A1 (en) 2009-07-01
RS20090104A (en) 2010-06-30
US7696213B2 (en) 2010-04-13
BRPI0716749B1 (pt) 2020-10-06
ES2366489T9 (es) 2013-12-27
NO20091141L (no) 2009-03-31
CN101573358A (zh) 2009-11-04
BRPI0716749B8 (pt) 2021-05-25
EP2074122B9 (en) 2013-09-11
WO2008032162A1 (en) 2008-03-20
AU2007297212B8 (en) 2011-04-28
JP4718637B2 (ja) 2011-07-06
TW200820972A (en) 2008-05-16
CN101573358B (zh) 2012-05-30
CR10662A (es) 2009-04-17
EA200970207A1 (ru) 2009-08-28
EP2074122B1 (en) 2011-06-29
AU2007297212A1 (en) 2008-03-20
JP2010503653A (ja) 2010-02-04
CA2663401A1 (en) 2008-03-20
AR062785A1 (es) 2008-12-03
TN2009000085A1 (fr) 2010-08-19
WO2008032162A8 (en) 2009-03-26
TWI334353B (en) 2010-12-11
ES2366489T3 (es) 2011-10-20
BRPI0716749A2 (pt) 2014-02-18
NO342357B1 (no) 2018-05-14
US20100137279A1 (en) 2010-06-03
EA016388B1 (ru) 2012-04-30
KR101099926B1 (ko) 2011-12-28
US8633204B2 (en) 2014-01-21
CA2663401C (en) 2011-07-12
GEP20115306B (es) 2011-10-10
HN2007000267A (es) 2011-02-25
PL2074122T3 (pl) 2011-10-31
ATE514695T1 (de) 2011-07-15

Similar Documents

Publication Publication Date Title
GT200700077A (es) Compuestos de 4-metilpiridopirimidinona
UY39128A (es) Composiciones y métodos para modular la senda de señalización de wnt
GT200700039A (es) Derivados de triazolopirazina
GT200500226A (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa
GT200600306A (es) Inhibidores de glutamato agrecanasa
GT200600174A (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
GT200800170A (es) Compuestos de n-formil-hidroxilamina
GT200600430A (es) Compuestos de carboxiamina y metodos de uso de los mismos
GT200800258A (es) Compuestos de pirrolo-pirimidina y sus usos
ECSP11010930A (es) Nuevos compuestos químicos
GT200600428A (es) Compuestos organicos
CO6511283A2 (es) Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer
GT200500103A (es) 4-fenilamino-quinazolin-6-il-amidas
CO6511220A2 (es) Quinazolinas como inhibidores de los canales iónicos de potasio
SV2009003349A (es) Compuestos triciclicos, composiciones y procedimientos
GT200600205A (es) Nuevos herbicidas
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
GT200800218A (es) Compuestos organicos
BR112012033350A2 (pt) "composição e métodos para modular a via de sinalização de wnt"
GT200700058A (es) Nuevos derivados de piridazina
GT200600217A (es) Proceso para la sintesis de compuestos organicos
GT200800103A (es) 5-aril isoxazolinas para controlar plagas de invertebrados
ECSP11010778A (es) Amidofenoxiindazoles útiles como inhibidores de c-met
GT200600208A (es) Compuestos organicos
CR10674A (es) Inhibidores de la metaloproteinasa matriz